OBJECTIVE: To assess the efficacy of ciprofloxacin in the treatment of reactive arthritis (ReA) and anterior uveitis (AU) in a double-blind, randomized, placebo-controlled trial. METHODS:Seventy-two patients participated in this study, 56 with ReA and 42 with AU (26 patients had both ReA and AU). Ciprofloxacin (750 mg twice a day) was administered for 12 months with a 12-month followup. End points of the study included time to disease relapse and measures of disease severity. RESULTS: There was no difference between groups in time to disease relapse, joint inflammation, number of joints and enthesis involved in patients with ReA, or signs and symptoms of AU. CONCLUSION: Long-term treatment of ReA and AU with ciprofloxacin made no statistically significant difference to the natural history of these diseases or their severity.
RCT Entities:
OBJECTIVE: To assess the efficacy of ciprofloxacin in the treatment of reactive arthritis (ReA) and anterior uveitis (AU) in a double-blind, randomized, placebo-controlled trial. METHODS: Seventy-two patients participated in this study, 56 with ReA and 42 with AU (26 patients had both ReA and AU). Ciprofloxacin (750 mg twice a day) was administered for 12 months with a 12-month followup. End points of the study included time to disease relapse and measures of disease severity. RESULTS: There was no difference between groups in time to disease relapse, joint inflammation, number of joints and enthesis involved in patients with ReA, or signs and symptoms of AU. CONCLUSION: Long-term treatment of ReA and AU with ciprofloxacin made no statistically significant difference to the natural history of these diseases or their severity.
Authors: J D Carter; L R Espinoza; R D Inman; K B Sneed; L R Ricca; F B Vasey; J Valeriano; J A Stanich; C Oszust; H C Gerard; A P Hudson Journal: Arthritis Rheum Date: 2010-05
Authors: M Smieja; D W MacPherson; W Kean; M L Schmuck; C H Goldsmith; W Buchanan; L E Hart; J B Mahony Journal: Ann Rheum Dis Date: 2001-12 Impact factor: 19.103
Authors: T K Kvien; J S H Gaston; T Bardin; I Butrimiene; B A C Dijkmans; M Leirisalo-Repo; P Solakov; M Altwegg; P Mowinckel; P-A Plan; T Vischer Journal: Ann Rheum Dis Date: 2004-09 Impact factor: 19.103